Of the 37 patients, 18 had idiopathic PAH and 19 had congenital heart disease-associated PAH (10 after correction and 9 with shunts). Patients had a median age of 15.7 years (25th-75th percentiles, 13.0-17.2 yr) at enrollment; 57% of the population was female. At enrollment, 18 (48.6%) patients were incident and 7 (18.9%) were treated with phosphodiesterase type 5 inhibitors, 5 (13.5%) with endothelial receptor antagonist, 4 (10.8%, responders in vasoreactivity testing) with calcium channel blockers, and 3 (8.1%) with combination therapy (endothelial receptor antagonists 1 phosphodiesterase type 5 inhibitors). Their detailed clinical data and CPET parameters are listed in Table 1 . Patients in the CW group had lower peak systolic blood pressure (sBP; P = 0.007) and diastolic blood pressure (P = 0.019) than those in the non-CW group ( Table 1) .
The median follow-up time was 15.8 months (25th-75th percentiles, 12.5-26.8 mo), during which CW events occurred in eight (22%) patients, with one death from right heart failure, seven hospitalizations for PAH deterioration, and five escalations of PAH-targeted therapy during hospitalization. The eight patients all had worsening of World Health Organization functional class. No patients were lost to follow-up.
Markers with potential prognostic value (P , 0.1 in univariate Cox regression analysis) were included in the multivariate model ( Figure 1A ). After adjustment, peak sBP was identified as an independent prognostic factor for CW (hazard ratio, 0.807; 95% confidence interval, 0.665-0.980; Figure 1A ). The optimum cutoff value for predicting CW derived from a ROC curve was 119 mm Hg (c-statistic = 0.77; P = 0.021; sensitivity, 75%; specificity, 76%). In Kaplan-Meier analysis, patients with peak sBP of 119 mm Hg or higher had worse survival.
Subgroup analysis was performed in patients without shunts (idiopathic PAH plus congenital heart disease-associated PAH after correction). Peak sBP was the only multivariate predictor (hazard ratio, 0.717; 95% confidence interval, 0.554-0.927; Figure 1B ). The optimum value (119 mm Hg) derived from ROC curve (c-statistic = 0.82; P = 0.009; sensitivity, 75%; specificity, 80%) was the same as in the overall population. Kaplan-Meier analysis showed that patients with peak sBP of 119 mm Hg or higher had worse survival in this population.
During CPET, there were no significant adverse events, such as cardiac arrest, ventricular tachycardia, supraventricular tachycardia, syncope, chest pain, or dizziness. The reasons for stopping exercise were leg fatigue (65%), shortness of breath (22%), and general fatigue (8%). Mild ST-segment changes (1z3 mm) were detected in eight patients (22%), and moderate changes (.3 mm) in three patients (8%).
Discussion
CPET is a safe and informative tool to assess and monitor exercise tolerance in pediatric PAH (5) . In the present study, we investigated for the first time the prognostic value of CPET in pediatric PAH, demonstrating that peak sBP during CPET predicts CW, and for each further 5 mm Hg reduction in peak sBP the risk of CW is increased by 20% ( Figure 1A) .
It has been identified that patients with peak sBP of 120 mm Hg or higher had worse survival in an adult population (6) . This finding is replicated using our dataset and the adult cutoff value 120 mm Hg (log rank P = 0.004 in Kaplan-Meier analysis). We suggest peak sBP of 120 mm Hg can be used as a predictor both in pediatric and adult PAH.
The predictive value of peak sBP during CPET may be because of its relationship to right ventricular function. Cardiac output (CO) during exercise can be noninvasively estimated from CPET parameters, and we investigated its correlation with peak sBP. Peak sBP had strong positive correlations with peak CO (r = 0.749; P , 0.001) and the increase of CO from baseline to peak exercise (r = 0.733; P , 0.001), which indicated lower peak sBP was associated with worse right ventricle function.
In the present study, some patients were receiving PAHtargeted therapies before admission to our center, including endothelial receptor antagonists, phosphodiesterase type 5 inhibitors, or both. Because of their limited availability and cost, no patients received prostanoid therapy. This study is limited by small sample size. PAH is rare in children, and because of subject age and the need for parental consent, the sample size is smaller than in adult studies. To counter this, we combined idiopathic PAH and congenital heart disease-associated PAH analyses; however, this may have increased heterogeneity. The size and the heterogeneity may explain why no other CPET-derived parameters emerged as independent predictors of outcome. Because of safety issues, this study did not examine the invasive hemodynamic parameters during exercise. The age of patients enrolled (9-18 years) may also be a potential bias, and the cutoff value of peak sBP for predicting outcomes may not be valid for younger children.
Conclusions
Pediatric patients with PAH incapable of achieving a significant increase in peak sBP during CPET are more likely to have CW Definition of abbreviations: AT = anaerobic threshold; BMI = body mass index; bpm = beats per minute; BSA = body surface area; CO = cardiac output; CI = cardiac index; CPET = cardiopulmonary exercise testing; CW = clinical worsening; HR = heart rate; mPAP = mean pulmonary artery pressure; mRAP = mean atrial artery pressure; NT-proBNP = N-terminal pro-brain natriuretic peptide; PAH = pulmonary arterial hypertension; PAWP = pulmonary artery wedge pressure; peak 
Rare Genetic Variants in PARN Are Associated with Pulmonary Fibrosis in Families
To the Editor:
Rare genetic variation in genes related to telomere biology has been implicated in 10-20% of familial interstitial pneumonia (FIP), the inherited form of idiopathic interstitial pneumonia (1) . Recently, heterozygous rare variants (RVs) in the gene encoding polyadenylationspecific RNase deadenylation nuclease (PARN) were reported in six unrelated families with pulmonary fibrosis (2), consistent with reports of biallelic PARN RVs in children with dyskeratosis congenita (3) (4) (5) . Subsequently, heterozygous PARN RVs were identified in five patients with sporadic idiopathic pulmonary fibrosis (IPF) among 262 patients who underwent whole-exome sequencing (6) .
We queried whole-exome sequencing data from genomic DNA obtained from 188 unrelated FIP kindreds (7) for RVs in PARN, identified variants with a minor allele frequency ,0.001 among Caucasian patients in the Exome Aggregation Consortium database, and confirmed these RVs by Sanger sequencing. Using this approach, we found 13 unique PARN RVs in 12/188 (6.4%) unrelated families ( Figure 1) ; seven families (3.7%) had variants predicted to be proteinaltering (frameshift, nonsense, splicing, missense; Table 1 ). In five of these families (2.6% of the cohort), PARN RVs identified as likely to be damaging fully cosegregated with disease in individual family members. These PARN RVs included one nonsense, one frameshift, one splicing, and two missense variants. The two missense variants, Asn7His and Lys56Ans, are conserved and predicted to affect protein function. For the c.62015G.A splicing variant, we generated immortalized lymphocytes and performed complementary DNA sequencing; this confirmed that this variant results in alternative splicing, which is likely to affect PARN structure and function.
Surprisingly, in three families, intronic PARN variants that did not appear to affect mRNA splicing cosegregated with disease. Complementary DNA sequencing demonstrated that c.17823C.T does not affect splicing, indicating this is likely benign. Another intronic variant, c.703-11_703-10delAT, is located in an intron near a splice site but is not predicted to alter the canonical splice site or create a cryptic splice site. A third intronic PARN variant c.1006211G.A cosegregated with disease in one family but is not predicted to alter splicing. In this family, however, affected subjects share a novel cosegregating RV in the gene telomerase reverse transcriptase (Thr839Lys). Although available evidence suggests these intronic RVs are benign, their cosegregation with disease and association with otherwise unexplained short telomeres in affected individuals raises the possibility that these intronic variants have effects on PARN expression or other regulatory mechanisms.
In the remaining four families, PARN RVs did not fully segregate with disease. In two of these families, there was a family history of IPF through both parental lineages, making it possible that affected individuals inherited a different genetic risk factor through each parental line. In one family, an intronic PARN RV that could affect splicing (c.245175_245177delCCC) was identified in a patient with IPF, whereas the other affected individuals shared a frameshift variant (Phe418PhefsX6). In a different family, an affected individual with short peripheral blood mononuclear cell telomeres carried a missense RV (Ser498Asn) that is predicted to be deleterious (PolyPhen2 0.996) (8) , but the RV was not identified in the other family member with disease.
We measured peripheral blood mononuclear cell telomere length in all affected individuals from these families from whom sufficient DNA was available and found that all had telomere shortening adjusted for age (Table 1) . Thirteen of the 18 subjects tested (72%) had telomere length below the 10th percentile, whereas the others ranged from the 12th to the 22nd percentile. All these families were of Caucasian ancestry, and 62% of affected subjects were men. The median age at diagnosis was 60 years (range, 42-82 years), slightly younger than the median age of onset in our entire cohort of patients with FIP (66 years) (7) . Forty-three percent of affected subjects had a history of cigarette smoking. Baseline FVC was 68.5% (617.7%, SD) predicted,
